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Endothelial progenitor cells (EPCs) have great clinical value because they can be used as diagnostic biomarkers and as a cellular
therapy for promoting vascular repair of ischaemic tissues. However, EPCs also have an additional research value in vascular
disease modelling to interrogate human disease mechanisms. The term EPC is used to describe a diverse variety of cells, and we
have identified a specific EPC subtype called outgrowth endothelial cell (OEC) as the best candidate for vascular disease modelling
because of its high-proliferative potential and unambiguous endothelial commitment. OECs are isolated from human blood and
can be exposed to pathologic conditions (forward approach) or be isolated from patients (reverse approach) in order to study
vascular human disease. The use of OECs for modelling vascular disease will contribute greatly to improving our understanding
of endothelial pathogenesis, which will potentially lead to the discovery of novel therapeutic strategies for vascular diseases.
1. Introduction
There is growing interest in endothelial progenitor cells
(EPCs) because of their relevant diagnostic and therapeutic
clinical applications. The association of EPCs with cardio-
vascular events [1] and cancer progression [2] demonstrates
that EPCs have potential as both diagnostic and prognostic
biomarkers. Furthermore, there are many preclinical and
clinical trials that have reported benefits for a cell therapy
based on delivering EPCs to ischaemic tissues such as heart
[3], brain [4], retina [5], and limbs [6]. In the case of
ischaemic heart disease and ischaemic limbs, despite con-
flicting data, meta-analysis indicated that an EPC-based
cytotherapy is feasible, safe, and beneficial [7, 8]. This paper
will not further discuss the diagnostic and therapeutic value
of EPCs, but will focus on a lesser-known application for
EPCs, that is, their potential for modelling human disease
pathogenesis. Creating cellularmodels of human disease is an
important research area where EPCs can be readily used and
allows for the study of cellular and molecular mechanisms
of vascular disease in a “Petri-dish”. Here, we will discuss
methodology for EPC isolation and diﬀerent cell subtypes
and also present strategies to use EPCs as valuable tools to
model vascular disease.
2. EPCs for Disease Modelling
Study of human disease using in vitro-based models usually
requires large quantities of cells. This is why classically
immortalised cell lines had to be established for this purpose.
However, these cell lines lack a number of tumour suppressor
genes or overexpress oncogenes, which is a major drawback
when assessing cellular proliferation and survival. Therefore,
recent interest has drifted to the usage of human embryonic
stem (hES) and induced pluripotent stem (iPS) cells [9, 10],
as they can theoretically be converted into any somatic cell
type.We believe that EPCs, as a specific type of adult vascular
stem cell [11], have great potential for modelling human
disease. EPCs are easily isolated from peripheral and umbil-
ical cord blood, they are highly proliferative, possess a stable
and diploid karyotype, represent a very homogeneous cell
population that is endothelial lineage-committed, and are
amenable to in vitro manipulation and genetic modification.
In addition, diseases associated with epigenetic changes to
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cell function can be consistently studied through EPCs, as
there is no reprogramming process required, which removes
methylation or acetylation events, as is the case for iPS cells.
3. Isolation of EPCs
EPCs are isolated using two main methodologies: (a) cell
sorting technology using diﬀerent cell surface markers or (b)
in vitro cell culture of the blood mononuclear cell fraction
using specific substrates and media.
EPC cell sorting is dependent on the type and number of
markers used. However, since there is no agreed consensus
regarding the most appropriate combination of EPC-linked
markers [12], diﬀerent research teams have been sorting
diﬀerent cells using a diverse array of markers. Therefore,
although sorted cells are all named EPCs, they actually rep-
resent distinct cell types, and this is demonstrated by the lack
of consistency in reported studies using “EPCs” in various in
vitro and animal model-based systems.
An alternative approach for isolating EPCs is cell culture.
This is based on diﬀerential adhesion to specific substrates
and the subsequent growth potential of isolated cells in
culture. Using this methodology, two distinct types of EPCs
have been identified [13, 14]. Early EPCs that appear within
one week in culture are spindle-shaped cells that exhibit
some endothelial properties in vitro, such as AcLDL uptake,
Isolectin binding, and appearance of VEGFR2/CD31 on the
cell surface. Despite these endothelial characteristics, these
cells retain their haematopoietic nature, as demonstrated by
high expression of CD14 and CD45. In fact, we have recently
shown that early EPCs represent M2 alternative-activated
macrophages and proposed their renaming asmyeloid angio-
genic cells (MACs) [15]. Other names for this cell type
commonly found in the literature are circulating angiogenic
cells, haematopoietic EPCs, proangiogenic monocytes, and
vascular accessory cells [16].
The other EPC subtype is known as outgrowth endothe-
lial cells (OECs) [17]. OECs appear within four weeks in cul-
ture as a cobblestone-shaped cell monolayer, exhibiting great
proliferative potential and an unambiguous commitment to
the endothelial lineage [18, 19]. Many studies have clearly
described the OEC immunophenotype as being highly pos-
itive for the endothelial markers VE-cadherin, vWF, CD31,
CD36, CD105, CD146, VEGFR2, and Tie2; negative for
haematopoietic markers CD45 and CD14; and exhibit some
expression of progenitor cell markers CD34, CD117, and
CD133 [5, 17, 20]. OECs are also known as endothe-
lial colony-forming cells (ECFCs), late EPCs, and non-
haematopoietic EPCs. OECs are diﬀerent from circulating
mature endothelial cells due to the fact that they have a
higher proliferative potential, shorter doubling time, and
single-cell cloning capacity in contrast to mature endothelial
cells that have limited proliferative potential [13, 17, 21]. Ad-
ditionally, OECs retain properties of immature cells, such as
greater responsiveness/sensitivity to VEGF, FGF-2, and PlGF
[21], and continued expression of progenitor cell markers
CD34, CD133, and CD117 [5].
OECs have been shown to possess de novo tubulogenic
capacity in vitro by forming three-dimensional tubular
structures where cells interact with each other through the
junction protein VE-cadherin and form a distinct vessel-
like lumen [22]. This de novo blood vessel formation is also
demonstrated in vivo where human OECs are transplanted
subcutaneously in a collagen-fibronectin matrix into im-
munodeficient mice and eﬃciently form perfused chimeric
blood vessels [18, 23, 24]. Using rhesus monkey-derived
OECs in this mouse experimental system, it was recently
shown that there was a decreased potential to form func-
tional capillaries with chronological age [25]. Most impor-
tantly, it has been demonstrated that OECs directly incorpo-
rate into damaged ischaemic vasculature in vivo as reported
using diﬀerent animal models such as the murine hind limb
ischaemia [13], rabbit carotid artery injury [26], the porcine
myocardial infarction [27], andmurine retinal ischaemia [5].
For the specific purpose of vascular disease modelling,
OECs should be the preferred EPC subtype to use, as they
are currently the only EPCs with both great proliferative
potential and unequivocal endothelial phenotype.
4. Approaches for Disease Modelling with OECs
In disease modelling, the classical “reverse” and “forward”
approaches used for hESCs are fully applicable to OECs
(Figure 1). The “reverse” approach is based on studying
OECs isolated from patients, so that “disease-specific” cells
are derived and compared to “disease-free” cells. This ap-
proach is very useful as it provides a meaningful insight
into physiopathology although it has two drawbacks. First,
isolating OECs from certain patient groups may be prob-
lematic. For example, it is well known that diabetic patients
have a lower number of circulating EPCs and when they
are isolated, these cells show dysfunctional responses [28,
29]. The second drawback is that isolated OECs from
patients are “already diseased”, and as the “reverse” approach
is fundamentally retrospective, it may not be possible to
accurately model early stages of a pathogenic process.
The “forward” approach consists of studying “disease-
free” OECs that are exposed to defined disease-relevant
conditions, which can be as simple as environmental changes
(hypoxia, high glucose, and radiation) to more complex
genetic modifications by knocking down disease-related
genes. This approach is prospective and allows the study of
disease pathogenesis from early stages; however, there are
some technical challenges. Trying to mimic the pathologic
environment can prove very complicated as the in vivomilieu
usually comprises a diverse variety of factors combined
together. Reproducing the in vivo environment in vitro re-
quires multicell type culture systems. Another diﬃculty ap-
pears when the disease of interest is non-cell autonomous
and therefore is directly dependent on diﬀerent cell-cell
interactions, and more than one cell type is needed for
disease development and progression. A strategy that could
easily address this latter issue of multiple cell types is the
adjuvant use of iPS cell methodologies [30]. Generation
of iPS cells and OECs from the same donor can provide
the means to study OECs in various cell culture settings,
including co-cultures with iPS cells or any other iPS cell-
derived somatic cell type. This has the advantage that all
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Figure 1: Strategies for the use of EPCs in vascular disease modelling. A specific EPC cell subtype called OEC can be isolated from human
peripheral blood of both healthy donors and patients. In the forward approach, “disease-free” OECs are exposed to disease-relevant
conditions or genetic modifications, while in the reverse approach “disease-specific” OECs are studied in comparison to “disease-free”
OECs.
the diﬀerent cell types studied alongside OECs will have the
same donor which is ideal to avoid possible immunological
responses arising from allogeneic transplantation.
While OECs can be studied directly, they can also indi-
rectly facilitate the study of other supportive cells that can
modulate vasculogenic activity in vitro or in vivo. As with
fully diﬀerentiated endothelial cells, angiogenic activity in
OECs can be directed by cytokines released from proximal
myeloid cells, mesenchymal stem cells (MSCs) [24, 31],
mesenchymal stromal cells, fibroblasts [23], adipose stromal
cells [32], pericyte progenitors [33], astrocytes, neurons, and
MACs [15, 34]. Interestingly, a mechanism involving the
formation of nanotubes for the transport of organelles such
as mitochondria and lysosomes has also been reported [35–
37]. Delivery of miRNAs within microvesicles and exosomes
represent another way cells can communicate with OECs
[38, 39].
Despite these technical challenges, utilising OECs to gen-
erate cellular models of disease is an attractive methodology
that is already being used and optimised. We anticipate that
in the field of vascular biology, researchers will favour the use
of EPCs/OECs for disease modelling.
5. OECs Used As Disease Cellular Models
OECs derived from patients with chronic myeloproliferative
disorders (CMD) [40] indicated that this disease targets
mainly the haematopoietic system, as the BCR-ABL rear-
rangement or JAK2-V617F mutation were not present in
OECs. This finding highlighted that OECs are not the
adult “haemangioblast”, but represent adult stem cells fully
committed to the endothelial lineage.
OECs from patients with hereditary haemorrhagic
telangiectasia (HHT) [41] revealed abnormalities compatible
with vascular lesions, such as decreased endoglin expression,
impaired TGF-β signalling, disorganised cytoskeleton, and
failure to form cord-like structures. These findings described
a molecular mechanism to explain small-vessel fragility and
frequent bleeding in these patients.
To elucidate the role of EPCs in the pathobiology of
pulmonary arterial hypertension (PAH), OECs were isolated
from peripheral blood of PAH patients with mutations in the
gene-encoding bone morphogenetic protein receptor type II
(BMPRII) and control subjects. OECs from PAH patients
with BMPRII mutations were hyperproliferative when com-
pared to controls. Furthermore, the matrigel angiogenesis
assay demonstrated that in vitro tube formation was also sig-
nificantly impaired in OEC isolated from PAH patients [42].
Von Willebrand disease (vWD) is frequently associated
with angiodysplasia; therefore, the importance of vWF
expression was tested in endothelial cells and animal models.
vWF-deficient cells showed enhanced angiogenesis in vitro,
and vWF-deficient mice displayed increase angiogenesis in
vivo. These results were further confirmed by isolating OECs
from patients with vWD [43] which showed increased in
vitro angiogenesis, proliferation, and migration.
To study the role of the diabetic environment in EPC
function, OECs were exposed to high glucose, and umbilical
cords of diabetic mothers were used as the EPC source to
isolate OECs that had previously experienced diabetic condi-
tions in vivo [44]. Results demonstrated that exposure to high
glucose in vitro or a diabetic environment in vivo significantly
diminished OEC function such as colony formation, self-
renewal capacity, and capillary-like tube formation. This
study provided potential mechanistic insights into the long-
term cardiovascular complications observed in newborns of
diabetic pregnancies.
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6. Concluding Thoughts
OECs are a specific EPC sub-type that is starting to be used
for the study of vascular pathology.We encourage researchers
in the field of vascular biology to apply their diﬀerent in vitro
and in vivo models of angiogenesis to OECs. Combination of
forward and reverse approaches for human diseasemodelling
with OECs is an eﬀective system for the study of vascular
disease pathogenesis. As with any new technology, we foresee
some technical challenges when establishing disease models
at the cellular level; nevertheless, we remain optimistic that
utilising OECs for vascular disease modelling will improve
our understanding of disease that subsequently leads to the
development of novel therapies.
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